|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2010-3-19
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Daclizumab, a humanised monoclonal antibody, reduced multiple sclerosis disease activity in previous non-randomised studies. We aimed to assess whether daclizumab reduces disease activity in patients with active relapsing multiple sclerosis who are receiving interferon beta treatment.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD56,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Immunologic Factors,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-beta,
http://linkedlifedata.com/resource/pubmed/chemical/daclizumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1474-4465
|
|
pubmed:author |
pubmed-author:CHOICE investigators,
pubmed-author:ElkinsJacobJ,
pubmed-author:FongAliceA,
pubmed-author:KaufmanMichaelM,
pubmed-author:MontalbanXavierX,
pubmed-author:O'NeillGilmoreG,
pubmed-author:PyszHH,
pubmed-author:RoseJohn WJW,
pubmed-author:SheridanJamesJ,
pubmed-author:SimonJackJ,
pubmed-author:VollmerTimothyT,
pubmed-author:WangChungchiC,
pubmed-author:WynnDanielD
|
|
pubmed:copyrightInfo |
2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
381-90
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20163990-Adolescent,
pubmed-meshheading:20163990-Adult,
pubmed-meshheading:20163990-Antibodies, Monoclonal,
pubmed-meshheading:20163990-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:20163990-Antigens, CD56,
pubmed-meshheading:20163990-Brain,
pubmed-meshheading:20163990-Cell Proliferation,
pubmed-meshheading:20163990-Double-Blind Method,
pubmed-meshheading:20163990-Female,
pubmed-meshheading:20163990-Humans,
pubmed-meshheading:20163990-Immunoglobulin G,
pubmed-meshheading:20163990-Immunologic Factors,
pubmed-meshheading:20163990-Immunosuppressive Agents,
pubmed-meshheading:20163990-Interferon-beta,
pubmed-meshheading:20163990-Lymphocytes,
pubmed-meshheading:20163990-Magnetic Resonance Imaging,
pubmed-meshheading:20163990-Male,
pubmed-meshheading:20163990-Middle Aged,
pubmed-meshheading:20163990-Multiple Sclerosis, Chronic Progressive,
pubmed-meshheading:20163990-Multiple Sclerosis, Relapsing-Remitting,
pubmed-meshheading:20163990-T-Lymphocytes,
pubmed-meshheading:20163990-Treatment Outcome,
pubmed-meshheading:20163990-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
|
|
pubmed:affiliation |
Consultants in Neurology Multiple Sclerosis Center, Northbrook, IL, USA.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
